Skila, a Sela2 Company Inc

Skila’s Dr. Susan Dorfman and Pragmedic's Dr. Brian D. Smith have been featured at eyeforpharma’s Market Access Europe 2010 Conference in London, focusing on their editorial in the Journal of Medical Marketing’s special Market Access issue.

Skila has four of its experts featured in Volume 10.1 of the Journal of Medical Marketing. “Pricing, Market Access and the Return of Reality” is the title of the latest volume of the prominent peer-reviewed Journal of Medical Marketing.

Skila, a leading provider of knowledge agility and stakeholder collaboration management solutions, today announced a new and expanded Master Services Agreement (MSA) with Nycomed.

Skila, a leading provider of knowledge agility and stakeholder collaboration management solutions, announces that a Top-20 US pharmaceutical company has chosen Skila’s Launch Readiness™ solution for two of its upcoming product launches.

iKOL offers real-time knowledge® of more than 2.5 million leading thought leaders representing 400+ disease areas in more than 60 leading countries across thousands of hospitals and institutions.

Skila, A Sela2 Company, has recently expanded its active client base by closing nine expansions across five current clients in Q4 of its fiscal year, ending September 30, 2009.

Skila announces the launch of two new state-of-the-art solutions for facilitating launch preparation and clinical trial tracking in the life science industry.

Skila’s iAdvocate Mobile™ solution enhances the iAdvocate™ opinion leader management solution by enabling users to quickly and easily access their iAdvocate™ solution from smart phones.

Skila, A Sela2 Company, announces the addition of mobile capabilities for Skila solutions. Skila’s mobile solutions allow knowledge agility by enabling users to quickly and easily access their Skila solutions from smart phones.

Susan Dorfman, VP Global Marketing, and Sara Melo-Pereira, Director of Global Marketing, Skila have recently released an article in Pharmaceutical Executive regarding the challenges in measuring the value of KOL interactions with field medical teams.